POST FORUM SITE
ATTENDEES
SPEAKERS
PRESENTERS
​​​EXHIBITORS
INVESTORS
SPONSORS
SUPPORTERS
​​​SEEDS


​ABOUT 19th BEF

Confirmed Keynotes Include:

• Guillaume Vignon, Senior Vice President Business Development, BeiGene GmbH
• Jim DeMesa, CEO, Emerald Health Pharmaceuticals  –  “The Endocannabi-What? The Medical (and Investment) Potential of Cannabis”

• Alain Vertes, Managing Director, NxR Biotechnologies GmbH
• Alessandro De Concini, Senior Advisor, European Investment Bank
• Alex Mayweg, Partner, Versant Venture
• Alexander Kort, Senior Vice President, Corporate Development, Themis Bioscience GmbH
• Anders Kristensson, CEO, TikoMed
• Barak Singer, VP Business Development, Trendlines Medical
• ​Carlos Buesa, CEO, Oryzon Genomics SA
• Carlos de Sousa, CEO,  Immunicum AB
• ​Chandra Leo, Portfolio Manager, HBM Partners AG
• Charles Bailey, Head, Neuroscience Business Development & Licensing, Novartis Pharma AG
• Chris Maggos, Managing Director, Europe, LifeSci Advisors, LLC
• Christian Elling, Managing Partner, Lundbeckfond Emerge
• Constantine Chinoporos, CBO, Boston Pharmaceuticals, Inc.
• ​David Colpman, Director, Colpman Consulting Ltd.
• Daniel Barton, Director, Business Development, Biosceptre (UK) Ltd
• Daniel Parera, Executive-in-Residence, TVM Capital Life Science
• Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services
• Eduardo Vianna, CEO, Novago Therapeutics AG
• Elias Papatheodorou, CEO, Genkyotex S.A.
• Enza Di Modugno, Director, Global Business Development, Roche Partnering
• Eric de La Fortelle, Venture Partner, Seventure Partners
• Eric Halioua,President & CEO, PDC*line Pharma
• Esteban Pombo Villar, CEO, TargImmune Therapeutics AG
• ​Fintan Walton, CEO, PharmaVentures Ltd.
• Florence Dal Degan, R&D Innovation Sourcing Director, Novo Nordisk A/S
• Florian Schödel, Owner, Philimmune, LLC
• François Thomas, President & Managing Partner, Sofimac Innovation
• Frank Hensel, Senior Investment Manager, High-Tech-Gruenderfonds Management GmbH
• ​Göran Forsberg, CEO, Cantargia AB
• Graham Dixon, CEO, Neem Biotech Ltd.
• ​Guillaume Vignon, Senior Vice President Business Development, BeiGene GmbH
• Guy Spigelman, Vice President Portfolio Success, aMoon Fund
• ​Hakan Goker, Senior Investment Director, M Ventures
• Heinz Lubenau, Chief Operating Officer, Vaximm AG​
• Isabel Ferreira, Director, Global Business Development, F. Hoffmann-La Roche Ltd.
• Jacob Keidar, H.E. Ambassador, Israeli Embassy in Bern, Switzerland
• Jane Dancer, CBO, F-star Biotechnology Ltd.
• Jasper Bos, Vice President and Head of Healthcare, M Ventures
• Jason Rushton, Partner, Investments, Xeraya Capital 
• Jesus Martin-Garcia, Chief Executive Officer, GeNeuro SA
• Jérémie Mariau, CEO, ILTOO Pharma
• Ji Li, Venture Partner, Lilly Asia Ventures
• Jim DeMesa, CEO, Emerald Health Pharmaceuticals
• ​John Gustofson, Sr. Director, Ventures & Early Stage Collaborations, AbbVie Ventures 
• John Sinden, Chief Scientific Officer, ReNeuron Group PLC
• Jonathan Tobin, Investment Director, Arix Bioscience plc
• Jörg Neermann, Partner, LSP
• Juan Pedro Rodríguez Serrate, Associate Analyst - Healthcare, Edison Group
• ​Juergen Gamer, VP Business Development, Apogenix AG
• Kia Motesharei, VP & Global Head, Business Development, Neurology & Immunology, Merck KGaA
• Laszlo Kiss, Executive Director, Pfizer Ventures, Pfizer, Inc.
• Laura Corradini, Deputy Global Head BD&L, CNS , Boehringer Ingelheim International GmbH
  Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
• Loïc Vincent, Head Oncology & Immunology Research Partnerships, Takeda Pharmaceuticals International Co.
• Lubor Gaal, Senior Vice President, Head of Europe, Locust Walk
• Luca Bolliger, VP Corporate Licensing, Recordati S.p.A.
• Lynn Durham, CEO, Stalicla SA
• Magnus Björsne, CEO, AstraZeneca BioVentureHub
• Manfred Horst, Business Development Officer, Biophytis SA
• Marietta Wu, Managing Director, Quan Capital
• Mark Emalfarb, President and Chief Executive Officer, Dyadic International, Inc. 
• Mark Krul, Partner, Aglaia BioMedical Ventures 
• Mark Vaeck, CEO, Complix NV
• Markus Hosang, General Partner, BioMedPartners AG
• Markus Kalousek, Head of Pharma Search & Evaluation, Global BD&L, Novartis Pharma AG
• Matthias Müllenbeck, Director Global Oncology L&BD, Global BD & Alliance Management, Merck KGaA
• Michael Farley, Director, Valor Management SA
• Michael Motz, CBO, NETRIS Pharma
• Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG
• Michel Wurm, VP, Medical Affairs, Strategy and Business Development, Pharmaleads SA
• Ming Wang, President and CEO, Phanes Therapeutics, Inc.
• Nate Chang, Managing Director, Life Sciences Investment Banking, RBC Capital Markets
• Nathalie ter Wengel, European Head External R&D and Innovation, Pfizer, Inc. 
• Nooman Haque, Director of Life Sciences, Silicon Valley Bank
• Paola Casarosa, Corporate Vice President of Business Development & Licensing, Boehringer Ingelheim International GmbH
• Patrick Van Beneden, Partner, Healthcare, Gimv
• Paul Bikard, CFO, Sensorion SA
• Paul Hermant, Partner, Bird & Bird LLP
• Pekka Simula, CEO, Herantis Pharma Plc.
• Peter Dudek, Partner, MRL Ventures Fund
• Peter Hoang, President and CEO, TapImmune Inc.
• Phil L'Huillier, Head of Business Development, Europe & Middle East, MSD
• Ping Shek, Managing Director, Torreya Partners (Europe) LLP
• Rainer Lichtenberger, CEO, Atriva Therapeutics GmbH
• Rainer Strohmenger, General Partner, Wellington Partners
• Remi Droller, Managing Partner, Kurma Partners
• Roger Bullock, CMO, Oryzon Genomics S.A.
• Ronald Kempers, President & CEO, Mymetics Corporation
• Ron Lipsky, Investor Relations, MGC Pharma (Aust) Pty Ltd.
• Roy Amariglio, Partner, OrbiMed
• Savita Bernal, Strategic Marketing and Corporate Communication Director, ADOCIA
• ​Søren Bjønness, Director – Switzerland Representative, Euronext
• Søren Møller, Managing Partner, Novo A/S 
• Sofia Ioannidou, Director, Andera Partners
• Sten Verland, Partner, Sunstone Capital A/S
• Stéphane Degove, CEO, GamaMabs Pharma SA
• Stewart Kay, Director, Business Development, GlaxoSmithKline 
• Thibaut Roulon, Investment Director, Life Sciences Investments, Bpifrance
• Tim Dyer, CEO, Addex Therapeutics Ltd.
• Timm Jessen, CEO, Topas Therapeutics GmbH
• Timothy Herpin, Chief Business Officer, Caribou Biosciences, Inc.
• Timothy Luker, Sen Director, Emerging Technology & Innovation, BD, Eli Lilly and Company
• Tong Zhang, Managing Director, C-Bridge Capital
• Vanessa King, Venture Partner, Abingworth LLP
• Yochi Slonim, Co-Founder, CEO, Anima Biotech, Inc.
• Yuwen Liu, Founding Partner and CEO, Bohe Angel Fund
• Vincent Fert, Chairman & CEO, HalioDx
• William Hearl, CEO & Founder, Immunomic Therapeutics, Inc.
• William Rice, Chairman, CEO & President , Aptose Biosciences, Inc.
• William Shen, Executive Director, Mergers & Acquisitions, Bristol-Myers Squibb